PT  - JOURNAL ARTICLE
AU  - Meyerson, Nicholas R.
AU  - Yang, Qing
AU  - Clark, Stephen K.
AU  - Paige, Camille L.
AU  - Fattor, Will T.
AU  - Gilchrist, Alison R.
AU  - Barbachano-Guerrero, Arturo
AU  - Sawyer, Sara L.
TI  - A community-deployable SARS-CoV-2 screening test using raw saliva with 45 minutes sample-to-results turnaround
AID  - 10.1101/2020.07.16.20150250
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.16.20150250
4099  - http://medrxiv.org/content/early/2020/07/17/2020.07.16.20150250.short
4100  - http://medrxiv.org/content/early/2020/07/17/2020.07.16.20150250.full
AB  - Up to 70% of SARS-CoV-2 infections in working- and school-age people are asymptomatic (Poletti et al., 2020), creating anxiety over reopening workplaces and schools around the world. In the absence of effective treatments or a vaccine, peace of mind will come only with community-based SARS-CoV-2 screening, where many people are tested on a regular basis. However, recent models show that short sample-to-answer turnaround time will be a critical property of effective screening strategies (Larremore et al., 2020). Here, we describe an RT-LAMP test for SARS-CoV-2 in raw saliva that takes about 45 minutes from sample to answer and requires only simple equipment (pipettes and a heating source). The assay has a limit of detection of 100 virions per microliter, and targets two separate regions of the SARS-CoV-2 genome. By combining rapid sample-to-answer turnaround time with the use of saliva, our RT-LAMP assay provides a low-complexity, portable, and robust system for real-time community screening.Competing Interest StatementSome of the authors of this study (NRM, QY, CLP, SLS) are founders of Darwin Biosciences, who licenses the RT-LAMP assay described herein.Funding StatementWe thank the Burroughs Wellcome Fund (PATH award to SLS; PDEP award to NRM) and NIH (DP1-DA-046108 and R01-AI-137011 to SLS) for funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Colorado Boulder IRB determined that this study is not research involving human subjects as defined by DHHS and/or FDA regulations and therefore does not require IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript.